Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

A non-binary transfeminine person experienced significant hair regrowth after starting finasteride, minoxidil, microneedling, and hormone replacement therapy with estradiol. They encourage trans individuals concerned about hair loss to consider estrogen as it has greatly improved their hair condition.

The user is 2 months post-hair transplant with 6,000 grafts using the DHI method and is using oral finasteride, minoxidil, and vitamins. They are seeking feedback on their progress.

Hair loss treatments are being tested on mice, with methods like minoxidil and stem cell therapy showing promising results. However, human trials are still years away, leading to humorous frustration about mice benefiting first.

Microneedling stimulates hair growth through stem cell activation during wound healing, not just increased blood flow. Other methods like showers or supplements don't replicate this effect.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

Creatine supplementation may increase DHT levels, potentially affecting hair loss. A study is examining this effect, with participants taking 5 grams of creatine daily for six months.

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

The review discusses traditional hair loss treatments like minoxidil and finasteride, and newer options like Low-Level Laser Therapy, microneedling, and platelet-rich plasma for androgenetic alopecia. It highlights the need for more high-quality trials to assess these treatments' effectiveness and standardized protocols for emerging therapies.

The post discusses a theory that hair regrowth after transplant is due to the angiogenesis process (new blood vessels forming), not because the transplanted hair is unaffected by DHT. The responses highlight the established belief in 'donor dominance' (the importance of the hair's origin in transplantation) and skepticism about the new theory.

DUPA and retrograde alopecia may not be solely DHT-based, and a biopsy is crucial for accurate diagnosis and treatment. Treatments mentioned include dutasteride, oral minoxidil, pioglitazone, clobetasol, calcipotriol, ketoconazole, and doxycycline, depending on the specific condition.

A user is planning to get extensive blood tests before starting Finasteride and is seeking advice on which tests are necessary. They are concerned about the cost and potential redundancy of some tests.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.

A user reported noticeable hair regrowth using a 272 diode red light therapy hat over 11 months without Minoxidil or Finasteride. Opinions vary on its effectiveness compared to traditional treatments, with some suggesting combining therapies for better results.

Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Finasteride may cause hair shedding as part of the regrowth process, but there are no controlled trials confirming this. The shedding idea is mostly based on anecdotal reports and comparisons to how minoxidil works.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

Liposomal formulations of finasteride and minoxidil may enhance drug delivery to the skin and hair follicles more effectively than traditional solutions, potentially improving treatment outcomes. However, more human clinical trials are needed to confirm these benefits.

Testing the effectiveness of Verteporfin as a potential treatment for hair loss, with users discussing their thoughts on its long-term results. Treatments mentioned include Minoxidil, Finasteride, and RU58841.

Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.

User shared 13 months of progress using finasteride, microneedling, vitamins, and scalp care, and recently started stemoxydine. The post includes before and after photos.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

A recent discovery in hair cloning identified a previously unknown cell type essential for hair follicle growth, which could potentially make lab-grown hair viable if translated to humans. However, skepticism remains due to past delays and the challenges of replicating results in humans and making the process affordable.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.

Finasteride and minoxidil are commonly used for hair loss, with RU58841 and microneedling also showing effectiveness. Oral minoxidil and dutasteride are noted for their impact, while side effects and alternative treatments like ketoconazole and natural DHT blockers are discussed.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.